Global office locator

Need to accelerate recruitment for a challenging lactation study? In one recent study, ICON enrolled six participants within one week after recruitment had stalled elsewhere for more than a year. By combining targeted re...

Analytical evidence is becoming the cornerstone of biosimilar development. With regulators increasingly open to reducing certain comparative clinical efficacy studies, the quality of bioanalytical data has never been mo...

Scientific publication collaboration made easier. PMSolution is an integrated start-to-finish process designed specifically for medical communications teams. Task reminders and version control. Review and approval tracki...

Patient safety is under growing pressure as sponsors manage rising data volumes, evolving regulations and more complex global safety operations. At World Patient Safety Congress Europe, visit ICON at booth \#422 to find...

The transition period for Italy's new serialisation framework is already underway. With dual systems operating until February 2027, early planning will be critical to reducing risk, avoiding implementation bottlenecks a...

Lactation studies are about more than compliance. They help sponsors make informed development decisions, strengthen product labeling, mitigate regulatory risk, and support patient safety. ICON combines specialised exper...

Join Dr. Mark Sorrentino, Vice President, ICON, for a practical deep dive into how ICON and Advarra are helping sponsors build more executable protocols by identifying risks earlier and embedding feasibility into study d...

At ICON, our work is centred on accelerating the development of therapies for patients worldwide. During 2025, we supported more than 1,370 clinical studies involving over 411,400 patients and contributed to 25 unique p...

C5 inhibitors require meningococcal vaccination. Natalizumab calls for JCV monitoring, anti-CD20 therapies necessitate hepatitis B screening, and anti-amyloid therapies depend on MRI monitoring. Together, these examples ...

ICON Biotech will be onsite at OCT Southern California taking place 15-16 September at the Hyatt Regency La Jolla at Aventine, San Diego. Visit us at Booth \#26. Our team will be available to discuss how ICON Biotech sup...

Building confidence in immunisation requires clear, trusted, and culturally relevant communication. Public health organisations, including WHO, UNICEF, and CDC, continue to highlight the importance of education and tailo...

It's not just GLP-1s anymore. Researchers are developing dual and triple agonists that combine GLP-1 with GIP and glucagon to maximise metabolic efficacy. Learn how engaging multiple pathways synergistically may suppress...